Announcements
- Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
- Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference
- Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
- Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
- Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
- Akero Therapeutics Announces Pricing of Public Offering of Common Stock
- Akero Therapeutics Announces Proposed Public Offering of Common Stock
- Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
- Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH
More ▼
Key statistics
On Friday, Akero Therapeutics Inc (0K4:BER) closed at 17.00, 58.88% above the 52 week low of 10.70 set on Oct 31, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.93 |
---|---|
High | 17.18 |
Low | 16.84 |
Bid | 17.11 |
Offer | 17.60 |
Previous close | 17.25 |
Average volume | 0.00 |
---|---|
Shares outstanding | 69.15m |
Free float | 58.77m |
P/E (TTM) | -- |
Market cap | 1.30bn USD |
EPS (TTM) | -3.20 USD |
Data delayed at least 15 minutes, as of May 31 2024 19:30 BST.
More ▼